Weight-Loss Drug Wars Take New Turn: Hims & Hers Stock Plunges as Novo Nordisk Gains Ground

The battle for your waistline just got a whole lot more expensive—for investors, at least.

Market Whiplash in the Pharma Arena

One minute you're riding high on consumer telehealth trends, the next you're watching your portfolio get a crash diet. The latest clinical or competitive tremor—details are scarce but the impact isn't—sent shares of Hims & Hers into a tailspin. Across the ring, industry titan Novo Nordisk flexed, its stock ticking upward as the landscape shifted beneath everyone's feet.

The Real Prescription? Volatility.

Forget steady growth; this sector runs on hype, hope, and the next headline. A single drug trial result or regulatory nod can redirect billions in market cap overnight—from one balance sheet to another. It's a high-stakes game where the only guaranteed weight loss is in your net worth.

Follow the Money (Until It Vanishes)

The smart money piles into perceived winners, fleeing perceived losers at the first sign of weakness. It's a classic momentum play, fueled more by trader sentiment than long-term health outcomes. After all, why cure the patient when you can just treat the stock price?

Another day, another brutal reminder that in biotech investing, you're not betting on science—you're betting on which horse Wall Street's algo-jockeys decide to whip next. The only thing shedding pounds faster than patients is shareholder value.

Key Takeaways

• Hims & Hers Health stock sank sharply Monday after the telehealth company said it would stop selling its compounded weight-loss pill.
• Novo Nordisk said it has filed a lawsuit against Hims over its compounded weight-loss drugs.

Hims & Hers Health shares are tumbling after a major blow to its weight-loss lineup.

Shares of the telehealth provider were down 25% Monday morning after Hims & Hers (HIMS) said in a statement over the weekend that it WOULD stop offering its compounded semaglutide pill, just days after launching the product.

The pill was marketed as offering the same active ingredient as Novo Nordisk's (NVO) Wegovy pill that received approval from the Food and Drug Administration in December, and was swiftly attacked by the Danish drugmaker. Novo Nordisk said Monday that it has filed a lawsuit against Hims & Hers, asking a court to "permanently ban Hims from selling unapproved, compounded drugs that infringe our patents," and is seeking damages. Shares of Novo Nordisk climbed about 4% in recent trading.

Hims & Hers, which called the lawsuit a "blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care," said it plans to "continue to fight to provide choice, affordability, and access."

Why This News is Important

Hims & Hers pulling its copycat pill from the market could reduce competition for Novo Nordisk. Rival Eli Lilly is expected to receive FDA approval for its own weight-loss pill later this year.

The FDA said on Friday that it plans to "take decisive steps to restrict" the use of GLP-1 active ingredients in compounded versions of the popular weight-loss medications, citing Hims & Hers by name in the statement.

Related Education

The announcement from Hims & Hers last week that it would start selling the compounded drug initially sent its shares higher, before giving up those gains as Novo Nordisk attacked the product. Shares of Hims & Hers, which has run into conflicts with Novo Nordisk previously, have lost more than 60% of their value over the past 12 months. Novo Nordisk shares are down about 40% over the same period, while Eli Lilly has gained more than 20%.